In 2022, a research group completed the largest trial in humans so far using exenatide, another GLP-1 agonist drug.

2022年，一个研究小组使用另一种GLP-1促效药艾塞那肽完成了迄今为止最大规模的人体试验。

If those results are promising, these experts are hoping that GLP-1 agonist drugs can one day give clinicians and patients another addiction treatment option.

如果这些测试有了结果，专家希望GLP-1促效药有一天能为临床医生和患者提供另一种成瘾治疗选择。